MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603

BACKGROUND: Carboplatin/paclitaxel (CP), with or without sorafenib, result in objective response rates of 18–20 % in unselected chemotherapy-naïve patients. Molecular predictors of survival and response to CP-based chemotherapy in metastatic melanoma (MM) are critical to improving the therapeutic in...

Descripción completa

Detalles Bibliográficos
Autores principales: Villaruz, Liza C., Huang, Grace, Romkes, Marjorie, Kirkwood, John M., Buch, Shama C., Nukui, Tomoko, Flaherty, Keith T., Lee, Sandra J., Wilson, Melissa A., Nathanson, Katherine L., Benos, Panayiotis V., Tawbi, Hussein A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457092/
https://www.ncbi.nlm.nih.gov/pubmed/26052356
http://dx.doi.org/10.1186/s13148-015-0092-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457092/
https://www.ncbi.nlm.nih.gov/pubmed/26052356
http://dx.doi.org/10.1186/s13148-015-0092-2

Ejemplares similares